loading page

Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis - A multicentre retrospective cohort study
  • +10
  • Hanke Wiegers,
  • Eva N. Hamulyák,
  • Stefanie E. Damhuis,
  • Jack R. Duuren,
  • Sarwa Darwish Murad,
  • Luuk J.J. Scheres,
  • Sanne Gordijn,
  • Jenneke Leentjens,
  • Johannes Duvekot,
  • Mandy N. Lauw,
  • Barbara Hutten,
  • Saskia Middeldorp,
  • Wessel Ganzevoort
Hanke Wiegers
Amsterdam UMC Locatie AMC

Corresponding Author:h.m.wiegers@amsterdamumc.nl

Author Profile
Eva N. Hamulyák
Amsterdam UMC Locatie AMC
Author Profile
Stefanie E. Damhuis
Amsterdam UMC Locatie AMC
Author Profile
Jack R. Duuren
Amsterdam UMC Locatie AMC
Author Profile
Sarwa Darwish Murad
Erasmus MC
Author Profile
Luuk J.J. Scheres
Radboudumc
Author Profile
Sanne Gordijn
UMCG
Author Profile
Jenneke Leentjens
Radboudumc
Author Profile
Johannes Duvekot
Erasmus MC
Author Profile
Mandy N. Lauw
Erasmus MC
Author Profile
Barbara Hutten
Amsterdam UMC Locatie AMC
Author Profile
Saskia Middeldorp
Radboudumc
Author Profile
Wessel Ganzevoort
Academic Medical Center
Author Profile

Abstract

Objective: to evaluate current practice and outcomes of pregnancy in women previously diagnosed with Budd-Chiari syndrome and/or portal vein thrombosis, with and without concomitant portal hypertension. Design and setting: multicentre retrospective cohort study between 2008-2021 Population: Women who conceived in the predefined period after the diagnosis of Budd-Chiari syndrome and/or portal vein thrombosis Methods and main outcome measures: We collected data on diagnosis and clinical features. The primary outcomes were maternal mortality and live birth rate. Secondary outcomes included maternal, neonatal and obstetric complications. Results: Forty-five women (12 Budd-Chiari syndrome, 33 portal vein thrombosis; 76 pregnancies) were included. Underlying prothrombotic disorders were present in 23 of 45 women (51%). Thirty-eight women (84%) received low-molecular-weight heparin during pregnancy. Of 45 first pregnancies, 11 (24%) ended in pregnancy loss and 34 (76%) resulted in live birth of which 27 at term age (79% of live births and 60% of pregnancies). No maternal deaths were observed, one woman developed pulmonary embolism during pregnancy and two women (4%) had variceal bleeding requiring intervention. Conclusions: The high number of term live births (79%) and lower than expected risk of pregnancy-related maternal and neonatal morbidity in our cohort suggest that Budd-Chiari syndrome and/or portal vein thrombosis should not be considered as an absolute contra-indication for pregnancy. Individualized, nuanced counselling and a multidisciplinary pregnancy surveillance approach are essential in this patient population.
12 May 2021Submitted to BJOG: An International Journal of Obstetrics and Gynaecology
17 May 2021Submission Checks Completed
17 May 2021Assigned to Editor
17 May 2021Reviewer(s) Assigned
21 Jun 2021Review(s) Completed, Editorial Evaluation Pending
27 Jul 2021Editorial Decision: Revise Major
25 Aug 20211st Revision Received
26 Aug 2021Submission Checks Completed
26 Aug 2021Assigned to Editor
26 Aug 2021Review(s) Completed, Editorial Evaluation Pending
29 Aug 2021Editorial Decision: Accept
Mar 2022Published in BJOG: An International Journal of Obstetrics & Gynaecology volume 129 issue 4 on pages 608-617. 10.1111/1471-0528.16915